This test is most useful if any of these apply to you.
Some inherited heart risk isn't reflected in your cholesterol results. One well-studied example is rs1333049 on chromosome 9. This common DNA variant is associated with coronary artery disease, which develops when plaque builds up in the arteries supplying your heart.
The association is firmly established, but using this single result to choose earlier scans or treatment remains an emerging application. Studies show a modest difference in disease risk between genotypes. They haven't established that prevention decisions based on rs1333049 alone improve health outcomes.
At this DNA position, the usual letters are G and C. You inherit one from each biological parent, so your result reads GG, GC or CC. C is the risk-associated letter. In populations where the association is established, risk generally rises with each additional C copy.
These are relative differences between groups. CC doesn't diagnose plaque or predict that you'll have a heart attack, and GG doesn't rule out inherited heart risk. Your absolute risk also depends on age, smoking, blood pressure, cholesterol exposure, diabetes, family history and other genetic variants.
This position lies in a region of DNA involved in regulating cell behavior. The region includes ANRIL and is near CDKN2A and CDKN2B. ANRIL is an RNA molecule that can influence gene activity; the nearby genes help control cell division. rs1333049 also marks a stretch of DNA containing other variants commonly inherited with it, so the association doesn't establish that this letter alone causes plaque.
Research in human heart and artery tissue suggests that the risk-associated region may affect genes involved in cell growth. Those tissue findings are exploratory: in one study, the individual gene-expression findings did not remain statistically convincing after accounting for the many comparisons made. The precise mechanism remains unresolved.
Large studies consistently associate this region with developing coronary disease. Some measured rs1333049 directly; others measured neighboring variants that are often inherited with it. Those neighboring markers support the regional association, but their genotype letters must not be read as rs1333049 results.
| Who Was Studied | Which Variant Was Studied | What Was Found |
|---|---|---|
| About 41,000 people, including 12,004 with coronary disease | rs1333049 | Each additional C copy was associated with about 24% higher odds of coronary disease. |
| About 168,000 adults without coronary disease across 16 follow-up studies | rs1333049 and closely linked 9p21 markers | Each additional risk allele was associated with about 19% higher risk of a first coronary event. |
| About 22,000 initially healthy white women followed for about 10 years | The neighboring variant rs10757274 | AG was associated with about 25% higher cardiovascular risk and GG with about 32% higher risk, compared with AA. |
The first-event studies used outcomes that could include heart attack, coronary death and artery-opening procedures. Their estimates aren't all estimates of heart attack alone. The association remained after adjustment for standard risk factors, although that statistical independence doesn't automatically make the result useful for choosing treatment.
Direct evidence also comes from a Taiwanese community cohort of about 2,100 adults followed for nearly eight years. Each C copy was associated with about 78% higher heart attack risk; CC was associated with about 2.4 times the risk of GC and GG combined. These estimates were substantially larger and less precise than those from the large pooled studies, so they shouldn't be treated as the expected effect for everyone with this genotype.
Several studies connect the variant with plaque burden. In about 770 adults in the Bruneck study, each C copy was associated with 46% higher odds of having neck-artery plaque at the first assessment. It was also associated with 73% higher odds of plaque progression over the following five years. These are changes in odds, not the percentage of carriers who developed plaque.
A collaboration of 21 studies examined coronary disease on angiograms. Among roughly 21,000 participants with coronary disease, each risk allele was associated with about 10% higher odds of disease involving several arteries rather than one. This analysis combined rs1333049 with related 9p21 markers.
Large genetic studies have also linked the 9p21 region to coronary calcium. A Chinese study measuring rs1333049 found associations with coronary disease and subsequent events in participants with calcification, but did not detect them in participants without calcification. That subgroup finding doesn't establish that the genotype matters only after calcium appears.
The findings differ across measures of artery health. In older French adults, rs1333049 was associated with carotid plaque but not with the thickness of plaque-free artery walls. Finnish studies found no association with artery-wall thickness or the ability of arteries to widen. A small Han Chinese study found an association with coronary plaque progression in participants without diabetes, but not in those with diabetes. These differences limit how confidently the genotype can predict an individual's plaque progression.
The 9p21 region has also been associated with ischemic stroke. These strokes occur when blood flow to part of the brain is blocked. A pooled analysis of about 34,100 stroke cases and 153,400 controls found about 11% higher odds per risk allele at rs10757278 or closely linked markers. This was neighboring-variant evidence, not an estimate for each C copy at rs1333049.
In that analysis, the association was detected for strokes involving large-artery disease, but not for small-vessel or heart-related clot subtypes. A later meta-analysis also found associations involving rs1333049, with results varying by ancestry and genetic model. These findings don't establish this single genotype as a useful stand-alone stroke prediction tool.
Variants in the same coronary-risk region of 9p21 have also been linked to abdominal aortic size and aortic aneurysm. Those findings come from studies of related markers rather than direct per-C estimates at rs1333049. Nearby variants associated with type 2 diabetes are distinct from the main coronary disease signal, so this result should be interpreted for its coronary association.
The evidence is different once you already have coronary disease. In a pooled analysis of about 103,000 Europeans with established disease, rs1333049 did not meaningfully predict another heart attack or coronary death. An earlier analysis comparing first and subsequent events reached a similar conclusion. The larger study did find a modest association with later artery-opening procedures, so it would be too broad to say the variant predicts nothing after diagnosis.
Smaller studies have reported conflicting results. In the GRACE study, GC and CC combined were associated with about 49% higher risk of repeat heart attack or cardiac death over six months compared with GG. A Japanese study reported fewer repeat heart attacks among CC carriers. A separate study of 472 people reported an exploratory interaction between carrying C and having shorter telomeres in white blood cells. Telomeres are protective DNA structures at the ends of chromosomes.
The large pooled results provide stronger evidence than these smaller, inconsistent findings. They fit a stronger association with developing coronary disease than with recurrent heart attack, but they don't prove exactly which biological process explains the difference. If you already have coronary disease, this genotype has little established value for changing your treatment.
You can carry C even when your cholesterol and blood pressure look ordinary. In the Heart and Soul study, rs1333049 was not associated with lipids, blood pressure, inflammatory markers or measured heart structure and function. A later pooled analysis did find a small association with triglycerides, so complete independence from every lipid measure would overstate the evidence.
A genetic association can be real without improving prediction much. In the study of about 22,000 women, adding the neighboring rs10757274 genotype to standard risk factors, hs-CRP and family history barely changed prediction and did not improve risk classification. Some studies have reported more reclassification in selected groups, but changing a risk category doesn't by itself show that the new category leads to better outcomes.
A family history of early heart disease can already justify closer attention to prevention. A C result may add context, but there is no validated rule that assigns an earlier scan, a particular medicine or a different treatment target from GG, GC or CC alone.
Observational studies suggest that eating patterns may influence the risk associated with this region. An analysis included about 8,100 INTERHEART participants and a separate group of about 19,100 FINRISK participants. The excess risk associated with 9p21 markers was weaker among people eating more vegetables and fruit. The main reported interaction involved neighboring variants, so it should not be presented as a proven rs1333049-specific dietary effect.
The Taiwanese cohort measured rs1333049 directly and reported a weaker CC-associated heart attack risk among people whose diets more closely resembled a Mediterranean pattern. This compared different groups of people; it didn't show that changing an individual's diet reduced their genetic risk by a specified amount. The dietary subgroup estimates were imprecise.
A study of young adults also linked diet to blood-protein patterns associated with the neighboring rs2383206 variant. It measured protein patterns at one point in time, not fewer heart attacks. These studies support investigating diet–gene interactions, but they don't establish a diet or supplement that cancels this genotype's effect.
A coronary disease polygenic risk score combines information from many DNA variants. It generally captures more inherited susceptibility than rs1333049 alone. A score for high cholesterol is a different score with a different outcome, even if both appear on the same genetic report.
Reanalyses of statin trials found larger treatment benefits in groups with high multi-variant genetic scores. In JUPITER, the estimated number treated over ten years to prevent one coronary event was 25 in the high-score group versus 66 in the low-score group. The corresponding estimates in ASCOT were 20 and 57. These were projected ten-year estimates from retrospective genetic analyses of trials, not results from ten-year trials that assigned treatment according to genotype, and they can't be applied to rs1333049 alone.
The 2026 PROACT report found silent coronary plaque in people selected using a high coronary disease polygenic score. It reported early feasibility and imaging findings, not proof that this screening strategy prevents heart attacks. There was no comparable low-score imaging group.
Current dyslipidemia guidance recognizes a high polygenic risk score, when already measured, as information that can inform a prevention decision. That evidence concerns multi-variant scores. A CC result doesn't establish that you have a high polygenic score or automatically make another genetic test necessary.
Your inherited rs1333049 genotype is permanent. One reliable result is generally enough, and repeating it won't show whether prevention is working. Follow-up instead tracks your blood pressure and lipid results. If you start or intensify cholesterol-lowering medication, a usual lipid check is four to twelve weeks afterward and then periodically, often every three to twelve months, once treatment is stable; this schedule comes from treatment monitoring, not your 9p21 genotype.
9p21 Genotype (rs1333049) is best interpreted alongside these tests.
9p21 Genotype (rs1333049) is included in these pre-built panels.
Learn about one inherited contributor to heart disease and how it fits with your other risk factors.
Screens 140+ genes linked to inherited cholesterol disorders and other hidden drivers of heart disease risk.
162 biomarkers